Skip to main content
New radiotracer firm unveiled by Denos Health Management

Denos Health Management has launched Zionexa, a company established from proceeds of Denos' sale of Cyclopharma France that aims to improve patient care through breakthrough companion therapeutic and diagnostic radiotracers. Zionexa intends to begin the submission process to obtain FDA clearance for the PET tracer EstroTep, the EGFR protein-targeting IMAKinib tracer for lung cancer, and another fluorine-based radiopharmaceutical this summer.

Full Story: